When Is Opioid Relapse Risk Highest After Detox?
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
The period immediately after opioid detox deserves particular attention. Withdrawal may have improved, but opioid tolerance can be lower, cravings and triggers may return, and a person may suddenly regain access to the same environment in which opioids were previously used.
There is no single day or week when every person’s relapse risk is highest. However, the first days and weeks after detox or discharge can be a particularly vulnerable period, especially when there is a gap in continuing treatment, cravings return, access to opioids is easy or opioid tolerance has fallen.
Research examining overdose after inpatient detoxification has found a concentration of overdose events in the first two weeks after discharge. This does not mean risk disappears after two weeks. Relapse and overdose vulnerability can continue for months or longer if opioid use disorder remains untreated.
Related: The period immediately after stopping opioids can be especially difficult. See our explanation of the transition from opioid dependence to naltrexone treatment.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-informed educational resource and is awaiting formal clinical approval. Until formal review has been completed, it should not be represented as medically reviewed.
View Dr Fergus Law’s professional profile
The Highest-Risk Period Is Better Understood as a Window, Not a Deadline
Families often ask whether there is a particular day after opioid detox when the risk of relapse is greatest.
Recovery does not work according to a fixed timetable.
Some people may experience intense cravings immediately after detox. Others may initially feel stable and encounter greater difficulty when they return to work, relationships, stress, pain or previous opioid-using environments.
The evidence is clearer about overdose vulnerability. Studies of people leaving detoxification and other opioid-treatment settings have repeatedly identified the period immediately after discharge or treatment cessation as particularly important.
Treat the first days and weeks after detox as a period requiring active treatment and planning, but do not assume that reaching day 14, day 30 or another milestone means relapse risk has disappeared.
In This Guide
Why Are the First Two Weeks After Detox So Important?
Research involving people discharged from inpatient substance-use treatment has identified substantial overdose vulnerability close to discharge.
In a Massachusetts study of more than 81,000 inpatient detoxification discharges, overdose risk was greatest close to detoxification. Among people who experienced an opioid overdose after leaving inpatient detoxification, 17% of those overdoses occurred within the first 14 days after discharge.
The researchers also reported that more than twice as many overdose events occurred during the first two weeks after discharge as during the following two weeks.
The percentage refers to the timing of overdose events among people in that study who subsequently experienced an overdose. It should not be interpreted as an individual’s personal probability of overdose.
Other studies examining treatment exit have also found particularly elevated mortality or overdose risk during the first two weeks after treatment ends.
These findings support intensive transition planning rather than sending someone home from detox with no clear next stage of treatment.
How Should the Period After Detox Be Viewed?
This timeline is not a prediction of what will happen to an individual. It highlights how treatment needs can change after withdrawal ends.
Transition Risk
The person moves from a controlled environment back into ordinary life. Medication, appointments, housing, transport and support should already be organised where possible.
Particularly Important
Research has identified a concentration of overdose events during this early period after discharge from detoxification and other treatment settings.
Risk Has Not Ended
Cravings, environmental triggers and treatment disengagement can still create substantial vulnerability during the remainder of the first month.
Continuing Treatment Matters
Relapse and overdose risk can persist. The Massachusetts study found that a substantial proportion of overdoses occurred more than four months after treatment exit.
Recovery plans should be reviewed according to the person’s actual cravings, treatment engagement, mental health, environment and opioid exposure risk rather than a calendar alone.
Why Can Relapse Still Happen Months After Detox?
The early post-detox period deserves special attention, but opioid use disorder does not expire after a few weeks.
Later relapse may be triggered by circumstances that were not present immediately after detox.
- a relationship breakdown;
- job loss or financial pressure;
- physical pain;
- bereavement;
- returning to a previous social group;
- stopping medication;
- dropping out of counselling;
- increasing alcohol or other substance use;
- depression, anxiety or insomnia;
- unexpected access to opioids.
Someone who has been stable for several months may therefore still need an established plan for responding to cravings or sudden opioid availability.
This is why the wider opioid relapse-prevention plan needs to extend beyond the immediate post-detox period.
Reduced Opioid Tolerance Can Turn a Return to Use Into an Overdose
Repeated opioid exposure can produce tolerance. When opioids are stopped, tolerance can decrease.
That means someone who returns to an amount they remember taking before detox may no longer tolerate that amount in the same way.
Higher Tolerance May Be Present
Repeated opioid exposure may mean the body has adapted to previously used amounts.
Tolerance Can Fall
The body’s ability to tolerate the previous opioid amount may decrease.
Previous Doses Can Become Dangerous
Returning to an amount used before detox may cause much stronger respiratory depression than expected.
Naloxone should be available where opioid exposure is possible, and family members or other close contacts should know how to respond to suspected overdose.
Cravings May Increase When the Person Returns to Familiar Life
A person may feel relatively stable while physically separated from their normal opioid-use environment.
Then they return home.
A familiar street, text message, argument, pain episode, payday, smell, person or emotion can suddenly reactivate an opioid craving.
That does not mean detox failed. It means detox did not remove every learned association connected with opioid use.
Read the dedicated guide: How to Stop Opioid Cravings After Detox or Rehab .
The Gap Between Detox and Continuing Treatment Can Be Dangerous
One of the most important questions is what happens immediately after detox ends.
If someone leaves withdrawal management without medication treatment, counselling, scheduled follow-up or a clear relapse plan, several protective layers disappear at the same time.
| After Detox | Potential Problem | Possible Protective Step |
|---|---|---|
| No next appointment | Treatment disengagement may begin immediately. | Arrange continuing care before discharge where possible. |
| No medication plan | Cravings or OUD symptoms may remain untreated. | Discuss appropriate MOUD before the transition home. |
| No naloxone | A future overdose may occur without an available reversal medication. | Provide or obtain naloxone and overdose education. |
| Immediate return to triggers | Old opioid-use pathways may reactivate quickly. | Plan environmental changes before discharge. |
| No craving plan | The person has to make decisions during a crisis. | Prepare specific actions and contacts in advance. |
This is also why detox alone may not be enough for opioid recovery .
What Can Increase Relapse Risk After Detox?
Timing matters, but the person’s individual circumstances may matter even more.
No Continuing Treatment
Leaving detox without evidence-based ongoing OUD treatment may remove an important layer of protection.
Strong Cravings
Increasing or persistent opioid cravings deserve prompt treatment review.
Previous Overdose
A history of overdose is an important clinical risk factor and should be discussed with the treatment team.
Easy Opioid Access
Contact with suppliers or opioid-using social networks can shorten the distance between craving and use.
Mental-Health Symptoms
Depression, anxiety, trauma symptoms or severe insomnia may contribute to instability and deserve assessment.
Pain
Acute or chronic pain may require a treatment plan that takes the person’s OUD history into account.
Alcohol or Other Drugs
Intoxication can affect judgment and increase exposure to environments associated with opioid use.
Loss of Daily Structure
Moving from a structured treatment setting into long periods of unplanned time can increase vulnerability.
Medication Can Reduce the Risks Associated With Leaving Detox Untreated
CDC recommends that clinicians offer or arrange evidence-based medication treatment for opioid use disorder.
FDA-approved medications for OUD are buprenorphine, methadone and naltrexone.
Buprenorphine
Buprenorphine can suppress withdrawal and reduce opioid cravings as part of ongoing OUD treatment.
Methadone
Methadone reduces opioid withdrawal and cravings and is an established long-term treatment for OUD.
Naltrexone
Naltrexone blocks opioid receptors and must be started after an appropriate opioid-free period to avoid precipitated withdrawal.
No medication is automatically the correct option for every person, and treatment should not be interrupted or changed based solely on information in an article.
Where Can Naltrexone Fit Into the Post-Detox Period?
Naltrexone works differently from buprenorphine and methadone because it blocks opioid receptors rather than activating them.
For appropriately selected patients who have completed the required opioid-free period, antagonist treatment may form part of a relapse-prevention plan.
Naltrexone should not be presented as guaranteeing the elimination of cravings or making overdose impossible.
Overdose vulnerability can also increase after antagonist coverage ends because opioid tolerance may be lower.
Long-Acting Naltrexone
Longer-acting formulations are intended to reduce reliance on repeated medication-taking decisions. This can be relevant where adherence is a major treatment vulnerability.
Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States. DeBinge treatment involving long-acting implant-based naltrexone takes place in Nassau, The Bahamas, following individual clinical assessment.
Learn more: Long-Acting Naltrexone Implant .
What Should Be in Place During the First Week After Detox?
Continuing treatment appointment
Ideally, the next stage of treatment should already be arranged before detox ends.
Medication plan
Confirm which medication is being used, how it should be taken and whom to contact if problems arise.
Naloxone access
Naloxone should be available wherever opioid exposure remains possible.
Craving-response plan
Identify who to call, where to go and what environment to leave when a strong craving develops.
Trigger reduction
Avoid unnecessary contact with people, places and routes closely associated with previous opioid use.
Daily structure
Plan sleep, meals, appointments, work and previously vulnerable periods rather than leaving the week completely unstructured.
Mental-health support
Address worsening anxiety, depression, trauma-related symptoms or severe sleep problems promptly.
Plan for a return to use
Decide in advance how immediate safety and rapid treatment re-engagement will be handled if opioid use occurs.
Warning Signs That the Post-Detox Plan Needs More Support
- cravings becoming stronger or more frequent;
- missing treatment appointments;
- stopping medication without medical guidance;
- contacting previous opioid suppliers;
- returning to opioid-using social groups;
- revisiting high-risk locations;
- increasing isolation;
- worsening sleep;
- increasing depression or anxiety;
- increasing alcohol or other drug use;
- romanticising previous opioid effects;
- actively searching for opioids.
These signs do not prove that relapse will occur, but they are reasons to review and strengthen the treatment plan rather than waiting for opioid use to happen.
Relapse Prevention Needs to Continue Beyond the First Weeks
The early period after detox deserves particular attention, but effective opioid relapse prevention also requires a longer-term strategy around medication, cravings, triggers, mental health, counselling, family support, overdose prevention and early response.
Do Not Wait to See Whether One Episode Becomes a Full Relapse
A return to opioid use after detox should prompt an immediate safety assessment.
Because tolerance may have decreased, overdose risk can be greater than the person expects.
Give naloxone if available, call emergency services immediately and remain with the person until professional help arrives.
Once immediate safety is addressed, reconnect with treatment and review medication, cravings, triggers, mental health and the current recovery environment.
Plan the Post-Detox Period Before Detox Ends
DeBinge provides addiction treatment in Nassau, The Bahamas. For suitable patients, assessment may include discussion of long-acting naltrexone alongside counselling and continuing recovery planning.
Treatment suitability depends on the individual’s current opioid exposure, detox status, medical history, medications, previous treatment and recovery needs.
Opioid Relapse Risk After Detox: FAQs
When is opioid relapse risk highest after detox?
There is no universal day when relapse risk peaks for every person. However, the first days and weeks after detox can be a particularly vulnerable period because tolerance may be reduced, treatment transitions occur and the person may return to previous triggers and opioid access.
Are the first two weeks after opioid detox especially dangerous?
Several observational studies have found high overdose vulnerability during the first two weeks after discharge or treatment exit. This supports particularly careful treatment linkage and overdose planning during the early post-detox period.
Does relapse risk disappear after two weeks?
No. Relapse and overdose risk can continue for months or longer. The first two weeks are an important period of concern, not a point after which the person becomes safe from relapse.
Why is overdose risk higher after detox?
Opioid tolerance can decrease during abstinence. If someone returns to an amount they previously used, their body may no longer tolerate it in the same way, increasing overdose risk.
Why can cravings become strong after someone returns home?
Returning home can reintroduce people, places, stress, pain and routines previously associated with opioid use. These learned cues can activate cravings even when acute withdrawal has ended.
What medications can reduce risk after opioid detox?
FDA-approved medications for opioid use disorder include buprenorphine, methadone and naltrexone. They work differently and the appropriate option depends on individual clinical circumstances.
Should someone have naloxone after detox?
Yes where opioid exposure remains possible. CDC recommends offering naloxone and overdose education to people with opioid use disorder and their household members or significant others.
Is completing detox enough to prevent relapse?
No. CDC does not recommend detoxification alone without medication treatment for opioid use disorder because of increased risks of returning to opioid use, overdose and overdose death.
What should happen immediately after opioid detox?
Continuing treatment should ideally already be arranged. Medication planning, counselling, naloxone access, trigger management, mental-health support and a clear response to cravings or return to use can all be considered.
What should I do if opioids are used again after detox?
Address overdose safety first. Give naloxone if overdose is suspected and contact emergency services. Then reconnect with treatment promptly and reassess the relapse-prevention plan.
Evidence Used in This Guide
CDC — Opioid Use Disorder: Treating
Current CDC guidance on medication treatment for opioid use disorder, detoxification, naloxone and ongoing care.
SAMHSA — TIP 63: Medications for Opioid Use Disorder
SAMHSA’s Treatment Improvement Protocol covering buprenorphine, methadone, naltrexone and other services supporting recovery from OUD.
Research — Opioid Overdose After Inpatient Detoxification
A Massachusetts cohort study examining overdose risk during transitions through inpatient detoxification, post-detoxification and residential treatment.
Research — Mortality After Treatment Exit
A California cohort study found particularly elevated mortality during the first two weeks after leaving opioid-dependence treatment.
Research — Overdose Risk After Leaving Treatment
A European cohort study found substantially elevated overdose mortality during the first month after leaving treatment compared with periods in treatment.
CDC — Preventing Opioid Overdose
Current CDC information on opioid overdose prevention, treatment of opioid use disorder and harm-reduction strategies.
Research findings describe groups of patients and should not be used to calculate an individual person’s relapse or overdose probability. Clinical guidance, approved products and regulatory information can change.
Related: The period immediately after stopping opioids can be especially difficult. See our explanation of the transition from opioid dependence to naltrexone treatment.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an educational resource concerning opioid relapse risk, overdose vulnerability and continuing treatment after detox. It is awaiting formal clinical approval.
View Dr Fergus Law’s professional profile
This Article Does Not Predict an Individual’s Relapse Risk
This page provides general educational information. Research describing periods of increased risk in groups of patients cannot determine exactly when an individual person will return to opioid use or experience an overdose.
This article does not diagnose opioid use disorder, determine treatment suitability or recommend a specific medication for an individual.
Do not abruptly stop methadone, buprenorphine, prescribed opioids or another prescribed medication based on this article.
Naltrexone requires appropriate opioid-free preparation before initiation. Starting antagonist treatment while significant opioid physical dependence remains can precipitate withdrawal.
If someone is unconscious, cannot be awakened, has very slow or stopped breathing, or an opioid overdose is suspected, administer naloxone if available and contact local emergency services immediately.
DeBinge is located in Nassau, The Bahamas. We do not operate a treatment facility in the United States. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.